In-Vitro, In-Vivo and RNA - Clinical Research Informer

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

Drug Discovery World

MARCH 26, 2024

Additional approaches, such as profiling of RNA and proteins, and the use of artificial intelligence (AI), could be key to providing a more comprehensive picture of a patient’s tumour and enable the use of optimised treatments. MT: Why was STORM attending the conference? We were there to present the latest findings from our research.

RNA

RNA In-Vivo In-Vitro DNA

FDA-approved drug sensitises brain cancer cells to radiotherapy

Drug Discovery World

JANUARY 23, 2023

This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “As GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval

FDA Approval Drugs In-Vivo In-Vitro

Taking an ‘upside-down’ approach to mRNA delivery

pharmaphorum

JANUARY 17, 2023

The intracellular barriers include endosomal escape, RNA sensors, and endonucleases. Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full potential.

Vaccination

Vaccination Vaccine In-Vivo In-Vitro

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. This method is generally used to deliver small interfering RNA (siRNA), but it can also be used for larger oligonucleotides too. Oligonucleotide. Anti-miRNA.

Bioavailability

Bioavailability In-Vivo RNA In-Vitro

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

AUGUST 12, 2020

Studies have identified the presence of two types of HIV-infected CD4+ T cells: ‘Transcriptionally inactive’ cells that do not typically produce viral RNA or viral proteins. Transcriptionally active’ cells in which HIV RNA is actively transcribed to make copies of the virus (despite long-term ART).

RNA

RNA Protein DNA In-Vivo

Organ-on-a-chip models in drug development

Drug Discovery World

APRIL 12, 2023

Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development

Development In-Vivo Drugs In-Vitro

Organ-on-a-chip models in drug development

Drug Discovery World

JANUARY 20, 2023

Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development

Development In-Vivo Drugs In-Vitro

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

Clinical Trials

Clinical Trials Clinical Trials Trials Antibody

Can liquid biopsies transform precision medicine?

Drug Discovery World

JANUARY 17, 2024

CTCs reflect high levels of tumour heterogeneity, represent clonal evolution, and are suitable for treatment selection, real-time longitudinal disease monitoring and in vitro/in vivo culture. Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer.

Medicine

Medicine DNA Genome Genomics

Preparing for new-era drug modalities with technology

Drug Discovery World

OCTOBER 13, 2022

Prior to the pandemic, messenger RNA (mRNA) drug development was niche and predominantly pointed at different disease targets, including infectious diseases and cancers. Why mRNA has potential . One aspect that makes mRNA technology popular with drug developers is that its proteins can be easily edited. The rise of global demand .

Drugs

Drugs Manufacturing Vaccination Vaccine

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Delveinsight

JANUARY 18, 2021

For instance, GTX-102 , an antisense therapy silencing the gene expression by binding to the RNA molecule behind the regulation of its expression, has also secured USFDA Fast Track Designation. Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system. GeneTx and Ultragenyx are co-developing the therapy.

Marketing

Marketing Gene Drugs Protein

The use of base editing in stem-cell based therapies

Drug Discovery World

JANUARY 23, 2023

This circumvents several technical challenges inherent to the genetic manipulation of differentiated cells in ex vivo culture or intact tissues. In cell therapy, regenerative and adoptive immunotherapies continue to bridge the gap between genetic engineering strategies and their clinical application.

Gene Editing

Gene Editing Gene Engineer DNA

Advances in neuroscience drug discovery

Drug Discovery World

FEBRUARY 22, 2024

According to Medicine Discovery Catapult, these include: “Navigating the complexity of the CNS; understanding the disease pathology, and accessing predictable in vitro and in vivo cell models 2 ”. Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In million deaths worldwide” 1.

Drugs

Drugs Gene Clinical Trials Clinical Trials

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

MAY 10, 2023

Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design. billion and take over 10 years.

Bioassay

Bioassay Genotoxicity Drugs In-Vivo

Clinical Research Informer

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

FDA-approved drug sensitises brain cancer cells to radiotherapy

Trending Sources

Taking an ‘upside-down’ approach to mRNA delivery

Cell-penetrating peptides as a delivery system for oligonucleotides

What the Glycome Can Tell Us About Persistent HIV Infection

Organ-on-a-chip models in drug development

Organ-on-a-chip models in drug development

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

Can liquid biopsies transform precision medicine?

Preparing for new-era drug modalities with technology

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

The use of base editing in stem-cell based therapies

Advances in neuroscience drug discovery

Accelerating NDA filing through faster carcinogenicity assessment

Stay Connected